Last €42.89 EUR
Change Today -0.60 / -1.38%
Volume 70.9K
DBV On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
NASDAQ GS
Frankfurt
Frankfurt
As of 11:35 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

dbv technologies sa (DBV) Snapshot

Open
€43.62
Previous Close
€43.49
Day High
€43.64
Day Low
€41.40
52 Week High
01/2/15 - €47.23
52 Week Low
05/2/14 - €14.61
Market Cap
823.9M
Average Volume 10 Days
40.8K
EPS TTM
€-1.42
Shares Outstanding
19.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DBV TECHNOLOGIES SA (DBV)

Related News

No related news articles were found.

dbv technologies sa (DBV) Related Businessweek News

No Related Businessweek News Found

dbv technologies sa (DBV) Details

DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.

48 Employees
Last Reported Date: 10/22/14
Founded in 2002

dbv technologies sa (DBV) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €280.0K
Compensation as of Fiscal Year 2013.

dbv technologies sa (DBV) Key Developments

DBV Technologies S.A. Announces Earnings Results for the Full Year Ended December 31, 2014

DBV Technologies S.A. announced earnings results for the full year ended December 31, 2014. For the full year 2014, the total income reached EUR 4.8 million, up from EUR 3.8 million for the same period in 2013. This increase primarily resulted from an increase in Research Tax Credit amounting to EUR 4.3 million over the period, compared to EUR 3.3 million a year earlier.

DBV Technologies Announces Publication in Journal of Allergy and Clinical Immunology of Data Demonstrating Epicutaneous Immunotherapy May Influence the Natural History of Allergy

DBV Technologies announced the publication of a set of experimental data in the Journal of Allergy and Clinical Immunology (JACI) demonstrating that early treatment with Epicutaneous Immunotherapy (EPIT®) using Viaskin® may induce protection from sensitization to other allergens. The pre-clinical data demonstrate that treatment with EPIT® could prevent further allergies by influencing the natural history of allergy via a Treg-dependent mechanism. This protective response induced by EPIT® is sustained after the end of treatment. In a murine model sensitized to a food allergen, EPIT® through the use of Viaskin ® can treat the first allergy, while protecting against anaphylaxis caused by sensitization to other food or respiratory allergens. The experiment shows that EPIT-induced Tregs significantly modified the humoral and cellular response, reduced Th2 cytokines, decreased eosinophilic esophagus infiltration and suppressed airway hyper responsiveness (AHR) and anaphylaxis. Epigenetic results are also provided suggesting that Milk-EPIT enhanced the methylation level of the promoter region of GATA-3, which may explain the prevention of sensitization to peanut and house dust mites, as well as the sustained protective response that was observed. As a conclusion, three major outcomes have emerged from this study: Demonstration of the protective effect of EPIT® to the sensitization to further allergens. Validation of the key role for regulatory T cells (Tregs) in the protection against further sensitizations. Determination of a sustained protective response induced by EPIT® after the end of treatment.

DBV Technologies Announces Board Changes

DBV Technologies provided an organizational update, which included appointing David Schilansky as Chief Operating Officer, Bertrand Dupont as Senior Executive Vice President, Technology, Charles Ruban as Senior Executive Vice President, Clinical Development & North American Operations and Laurent Martin as Senior Executive Vice President, Product Strategy & Regulatory Affairs. This new corporate organization reflects DBV's focus to become the leader in discovering, developing and commercializing food allergy treatments, while leveraging its Viaskin platform to develop innovative immunotherapy products. David Schilansky, previously Chief Financial Officer, has been appointed by the Board as Chief Operating Officer to support the CEO in the implementation of DBV's strategy. Bertrand Dupont, previously Chief Technical Officer, has been appointed as Senior Executive Vice President, Technology, and will be in charge of the continued development of the electrospray and upscaling of the production tools. Mr. Dupont will report to the CEO. Charles Ruban, Chief Development Officer, has been appointed Senior Executive Vice President, Clinical Development & North American Operations, permanently relocating to New York, NY mid-2015 to oversee DBV Technologies Inc., the company's US subsidiary. Mr. Ruban will lead DBV's launch-readiness effort for Viaskin Peanut, while overseeing DBV's Global Clinical Operations, Strategic Marketing, Market Access and Medical Affairs teams. Mr. Ruban will oversee late stage development while accelerating and maximizing Viaskin's access to the market. Mr. Ruban will report to the CEO. Laurent Martin, Director of Regulatory Affairs & Quality, will be appointed Senior Executive Vice President, Product Strategy & Regulatory Affairs, tasked with executing DBV's regulatory strategy and defining the path forward in food allergy. Mr. Martin will supervise project management of all food allergy programs. Laurent's new functions will be effective mid-2015 and will report to the CEO.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DBV:FP €42.89 EUR -0.60

DBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr751.00 DKK -12.00
Allergy Therapeutics PLC 24.00 GBp 0.00
Merck & Co Inc $60.28 USD -1.81
Sanofi €82.00 EUR -0.26
Stallergenes SA €52.72 EUR -0.28
View Industry Companies
 

Industry Analysis

DBV

Industry Average

Valuation DBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 104.6x
Price/Book 17.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 125.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DBV TECHNOLOGIES SA, please visit www.dbv-technologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.